Compounds for the treatment of disease associated with Clostridium difficile

A compound of formula (I): Formula ** ** R1 is selected from aryl, heteroaryl, carbocyclyl and optionally substituted heterocyclyl, where optional substitution with one or more substituents selected from halo, CN, NO2, R3, OR3, N (R3) 2, COR3, CO2R3, C (> = O) SR3, SR3, S (> = O) R3, SO2R3, NR4C (> = O) R3, NR4CO2R3, OC (> = O) NR3R4, NR4SO2R3, C (> = NR4) NR3R4, C (> = S) NR3R4, NR4C (> = NR4) NR3R4, NR4C (> = S) NR3R4, NR4C (> = O) NR3R4, CONR3R4 and SO2NR3R4; R2 is a bicyclic ring or tricyclic aromatic condensed 8-14 members optionally substituted system in which one or more of the carbon atoms may be replaced by N, O, S, SO or SO2 and wherein the optional substitution with one or more substituents selected from halo, CN, NO2, R3, OR3, N (R3) 2, COR3, CO2R3, C (> = O) SR3, SR3, S (> = O) R3, SO2R3, NR4C (> = O) R3, NR4CO2R3, OC (> = O) NR3R4, NR4SO2R3, C (> = NR4) NR3R4, C (> = S) NR3R4, NR4C (> = NR4) NR3R4, NR4C (> = S) NR3R4, NR4C (> = O) NR3R4, CONR3R4 and SO2NR3R4; R3 is selected from H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, carbocyclyl C3-C7 heterocyclyl C4-C7 aryl or heteroaryl of 5 or 6 members, any of which may be optionally substituted with one or more substituents selected from halo, CN, NO2, R4, OR4, N (R4) 2, COR4, CO2R4, C (> = O) SR4, SR4, S (> = O) R4, SO2R4, NR4C (> = O ) R4, NR4CO2R4, OC (> = O) NR4) 2, NR4SO2R4, C (> = NR4) N (R4) 2, C (> = S) N (R4) 2, NR 4 C (> = NR4) N (R4 ) 2, NR 4 C (> = S) N (R4) 2, NR 4 C (> = O) N (R4) 2, CON (R4) 2 and SO 2 N (R4) 2; R4 is selected from hydrogen, C1-C6 alkyl and C3-C7 carbocyclyl, optionally substituted by one or more halo atoms; or an N-oxide, salt, hydrate or pharmaceutically acceptable solvate thereof, for use in a method for treating a Clostridium difficile associated (CDAD) disease.